Izumi Akihiko, Tachibana Takayoshi, Ando Taiki, Tanaka Masatsugu, Kanamori Heiwa, Nakajima Hideaki
Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, 241-8515, Japan.
Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan.
Int J Hematol. 2022 Jan;115(1):69-76. doi: 10.1007/s12185-021-03217-4. Epub 2021 Sep 6.
This single-center retrospective study was performed in consecutive patients with acute lymphoblastic leukemia who relapsed after allogeneic hematopoietic cell transplantation (HCT) and received salvage therapy using inotuzumab ozogamicin (InO). Ten patients (median age: 27 years) treated between June 2018 and July 2020 who met the eligibility criteria were included in this study. Nine patients received InO in one cycle and seven of these patients achieved complete hematological remission after salvage chemotherapy including InO. Negative minimal residual disease was confirmed in all four evaluable patients. Eight patients were successfully bridged to the subsequent HCT. After HCT, veno-occlusive disease (VOD) developed in three patients, and caused the death of one. No patient received maintenance therapy. At present, five patients are disease-free and alive, and the overall and progression-free survival rates at 1 year were 60% and 40%, respectively. High rates of disease remission and bridging to HCT with comprehensive treatments including InO may have contributed to favorable outcomes. However, further investigation is needed to reduce post-HCT complications including VOD.
这项单中心回顾性研究纳入了接受异基因造血细胞移植（HCT）后复发并接受吉妥珠单抗奥唑米星（InO）挽救治疗的急性淋巴细胞白血病连续患者。2018年6月至2020年7月期间治疗的10例符合入选标准的患者（中位年龄：27岁）纳入本研究。9例患者接受了1个周期的InO治疗，其中7例患者在包括InO的挽救化疗后实现了完全血液学缓解。所有4例可评估患者均确认微小残留病阴性。8例患者成功过渡到后续的HCT。HCT后，3例患者发生了静脉闭塞性疾病（VOD），其中1例死亡。没有患者接受维持治疗。目前，5例患者无病存活，1年总生存率和无进展生存率分别为60%和40%。包括InO在内的综合治疗实现疾病缓解和过渡到HCT的高比率可能促成了良好的结果。然而，需要进一步研究以减少包括VOD在内的HCT后并发症。
